HIV cure strategies: How good must they be to improve on current antiretroviral therapy?

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Sax, Paul E ^a,b   Sypek, Alexis ^d   Berkowitz, Bethany K ^d   Morris, Bethany L ^d   Losina, Elena ^a,b,d,e   Paltiel, A David ^f   Kelly, Kathleen A ^d   Seage, George R ^c   Walensky, Rochelle P ^a,b,d   Weinstein, Milton C ^c   Eron, Joseph ^g   Freedberg, Kenneth A ^b,c,d,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BOSTON UNIVERSITY   (United States)

^f YALE UNIVERSITY   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CHEMOTHERAPY; CLINICAL EFFECTIVENESS; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RELAPSE; SENSITIVITY ANALYSIS; STEM CELL TRANSPLANTATION; UNITED STATES; ADULT; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HIV INFECTIONS; MALE; MIDDLE AGED; RECURRENT DISEASE;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; GENETIC THERAPY; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; STEM CELL TRANSPLANTATION;

EID: 84911935103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113031     Document Type: Article

References (50)

1. Moore RD, Bartlett JG (2011) Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis 53: 600-604.
2. Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, et al. (2013) Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 27: 973-979.
3. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371: 1417-1426.
4. Martin A, Bloch M, Amin J, Baker D, Cooper DA, et al. (2009) Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 49: 1591-1601.
5. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW (2013) Residual immune dysregulation syndrome in treated HIV infection. Advances in immunology 119: 51-83.
6. Farnham PG, Gopalappa C, Sansom SL, Hutchinson AB, Brooks JT, et al. (2013) Updates of lifetime costs of care and quality-of-life estimates for HIVinfected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr 64: 183-189.
7. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
8. Andrinopoulos K, Clum G, Murphy DA, Harper G, Perez L, et al. (2011) Health related quality of life and psychosocial correlates among HIV-infected adolescent and young adult women in the US. AIDS Educ Prev 23: 367-381.
9. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, et al. (2011) Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 117: 2791-2799.
10. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482-485.
11. Margolis DM, Hazuda DJ (2013) Combined approaches for HIV cure. Curr Opin HIV AIDS 8: 230-235.
12. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, et al. (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370: 901-910.
13. Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, et al. (2013) Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med 158: 84-92.
14. Siegel JE, Weinstein MC, Russell LB, Gold MR (1996) Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276: 1339-1341.
15. Ubel PA, Hirth RA, Chernew ME, Fendrick AM (2003) What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163: 1637-1641.
16. Vertex Pharmaceuticals Incorporated (2012) Kalydeco (ivacaftor) package insert. Available: http://pi.vrtx.com/files/uspi-ivacaftor.pdf. Accessed 18 August 2014.
17. Merck Sharp & Dohme Corp. (2006) Zolinza (vorinostat) [package insert]. Available: http://www.merck.com/product/usa/pi-circulars/z/zolinza/zolinza-pi.pdf. Accessed 18 August 2014.
18. Kavanaugh SM, White LA, Kolesar JM (2010) Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 67: 793-797.
19. Stamatovic D, Balint B, Tukic L, Elez M, Tarabar O, et al. (2011) Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies. Vojnosanit Pregl 68: 1026-1032.
20. RED BOOK Online (2013) Product Information for antiretroviral drug prices, Kalydeco, Zolinza, and Tivicay. Micromedex 2.0, Truven Health Analytics.
21. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954.
22. United Nations, Department of Economic and Social Affairs and Population Division (2009) World Population Prospects: The 2008 Revision, Highlights, Working Paper No. ESA/P/WP.210 Available: http://www.un.org/esa/population/publications/wpp2008/wpp2008-highlights.pdf. Accessed 10 June 2013.
23. Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, et al. (2006) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 43: 535-540.
24. Centers for Medicare and Medicaid Services (2012) Clinical Diagnostic Laboratory Fee Schedule 2012. Available: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.htm. Accessed 18 August 2014.
25. Centers for Medicare and Medicaid Services (2012) Medicare Physician Fee Schedule 2012. Available: http://www.cms.gov/apps/physician-fee-schedule/overview.aspx. Accessed 20 January 2014.
26. University HealthSystems Consortium (2008) CDP Online Report. Available: www.uhc.edu. Accessed 28 January 2014.
27. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, et al. (1998) The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 339: 1897-1904.
28. Mellors J, McMahon D (2014) Evaluating the safety and efficacy of single-dose romidepsin in combination with antiretroviral therapy in HIV-infected adults with suppressed viral load. NCT01933594. Available: http://clinicaltrials.gov/ct2/show/NCT01933594?term=romidepsin+hiv&rank=1. Accessed 23 Janaury 2014.
29. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, et al. (2010) Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 50: 1512-1520.
30. Panel on Antiretroviral Guidelines for Adults and Adolescents (2013) Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Department of Health and Human Services. Available: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult-oi.pdf. Accessed 18 August 2014.
31. Pepper PV, Owens DK (2002) Cost-effectiveness of the pneumococcal vaccine in healthy younger adults. Med Decis Making 22: S45-57.
32. Messou E, Chaix ML, Gabillard D, Minga A, Losina E, et al. (2011) Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr 56: 356-364.
33. Dotinga R (2010) Gene therapy for HIV inches forward. Available: http://health.usnews.com/health-news/managing-your-healthcare/genetics/articles/2010/06/16/gene-therapy-for-hiv-inches-forward. Accessed 7 May 2014.
34. US Department of Health and Human Services (2005) Medicaid drug price comparisons: average manufacturer price to published prices. Available: http://oig.hhs.gov/oei/reports/oei-05-05-00240.pdf. Accessed 16 January 2014.
35. Shenoy S (2011) Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematology Am Soc Hematol Educ Program 2011: 273-279.
36. National Bone Marrow Transplant Link (2010) Bone marrow/stem cell transplant frequently asked questions. Available: http://nbmtlink.org/resources-support/faq/faq-question8.html. Accessed 18 August 2014.
37. Kasiske BL, Cohen D, Lucey MR, Neylan JF (2000) Payment for immunosuppression after organ transplantation. American Society of Transplantation. JAMA 283: 2445-2450.
38. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, et al. (2013) Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 9: e1003211.
39. Lewin SR (2014) Finding a Cure for HIV: Much Work to Do. Ann Intern Med 161: 368-369.
40. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 48: 806-815.
41. Leelahavarong P, Teerawattananon Y, Werayingyong P, Akaleephan C, Premsri N, et al. (2011) Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand. BMC Public Health 11: 534.
42. Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, et al. (2004) A therapeutic HIV vaccine: how good is good enough? Vaccine 22: 4044-4053.
43. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
44. Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, et al. (2014) Costeffectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 59: 1692-1705.
45. Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, et al. (2011) Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 25: F21- 27.
46. Gebo KA, Moore RD, Fleishman JA (2003) The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV. Hopkins HIV Rep 15: 5-6.
47. Havrilesky LJ, Pokrzywinski R, Revicki D, Higgins RV, Nycum LR, et al. (2012) Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. Cancer 118: 386-391.
48. Dignan FL, Potter MN, Ethell ME, Taylor M, Lewis L, et al. (2013) High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD. Clin Transplant 27: E56- 63.
49. Elting LS, Cantor SB, Martin CG, Hamblin L, Kurtin D, et al. (2003) Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 97: 1541-1550.
50. Crespo C, Perez-Simon JA, Rodriguez JM, Sierra J, Brosa M (2012) Development of a population-based cost-effectiveness model of chronic graftversus- host disease in Spain. Clin Ther 34: 1774-1787.